Drug Profile
Research programme: siRNA hearing loss therapeutics - Quark Pharmaceuticals
Alternative Names: AHLi-11; QP-HL1; QP-HL2; QP-HL3Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Quark Pharmaceuticals
- Developer Quark Pharmaceuticals; State University of New York
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hearing disorders; Meniere's disease
- Discontinued Noise-induced hearing loss; Sensorineural hearing loss
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Meniere's-disease in USA (Parenteral)
- 28 Jan 2024 No recent reports of development identified for research development in Hearing disorders in USA (Parenteral)
- 30 Jan 2020 Early research development for Hearing disorders is ongoing in USA